Table 2 Treatment effectiveness and safety outcomes
|  | Analysis set (N = 660) |
|---|---|
Overall survival, n (%) | 656 (99.4) |
 Median (min–max), days (95% CI) | 319 (293–361) |
 Events / censored cases | 334 (50.6) / 322 (48.8) |
 Censored cases with 1-year survival | 216 (32.7) |
Time-to-treatment failure, n (%) | 660 (100.0) |
 Median (min–max), days (95% CI) | 116 (108–135) |
 Events / censored cases | 581 (88.0) / 79 (12.0) |
 Censored cases with 1-year treatment | 79 (12.0) |
Adverse eventsa, n (%) | |
 Diarrhea | 66 (10.0) |
 Renal impairment | 1 (0.2) |
 Severe infectious disease | 30 (4.5) |
 Anemia | 94 (14.2) |
 Peripheral neuropathy | 10 (1.5) |
 Bone marrow suppression (due to impaired hematopoiesis) | 461 (69.8) |
 Neutropenia-associated events | 382 (57.9) |
  Grade ≥ 3 eventb | 325 (49.2) |
 Febrile neutropenia | 119 (18.0) |